MediciNova Company Profile (NASDAQ:MNOV)

About MediciNova (NASDAQ:MNOV)

MediciNova logoMedicinova, Inc. is a biopharmaceutical company. The Company focuses on acquiring and developing small molecule therapeutics for the treatment of diseases with unmet medical needs and a commercial focus on the United States market. Its pipeline includes MN-166 (ibudilast), MN-001 (tipelukast), MN-221 (bedoradrine) and MN-029 (denibulin). MN-166 is an oral, anti-inflammatory and neuroprotective agent. MN-166 is in development for the treatment of several neurological diseases, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, and substance dependence and addiction. MN-001 (tipelukast) is an orally bioavailable small molecule compound, which is used for the treatment of fibrotic diseases, such as nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis. MN-221 treats acute exacerbations of asthma through intravenous infusion, bypassing constricted airways to deliver the drug to the lungs. MN-029 is used for the treatment of solid tumor cancers.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:MNOV
  • CUSIP: N/A
  • Web: medicinova.com
Capitalization:
  • Market Cap: $183.41 million
  • Outstanding Shares: 34,540,000
Average Prices:
  • 50 Day Moving Avg: $5.39
  • 200 Day Moving Avg: $5.74
  • 52 Week Range: $4.85 - $7.78
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -15.62
  • P/E Growth: -0.76
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.95 per share
  • Price / Book: 5.59
Profitability:
  • EBIDTA: ($10,500,000.00)
  • Return on Equity: -29.92%
  • Return on Assets: -26.19%
Debt:
  • Current Ratio: 21.88%
  • Quick Ratio: 21.88%
Misc:
  • Average Volume: 44,727 shs.
  • Beta: 0.04
  • Short Ratio: 37.46
 
Frequently Asked Questions for MediciNova (NASDAQ:MNOV)

What is MediciNova's stock symbol?

MediciNova trades on the NASDAQ under the ticker symbol "MNOV."

How were MediciNova's earnings last quarter?

MediciNova, Inc. (NASDAQ:MNOV) released its earnings results on Thursday, October, 29th. The company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.10) by $0.04. View MediciNova's Earnings History.

Who are some of MediciNova's key competitors?

Who are MediciNova's key executives?

MediciNova's management team includes the folowing people:

  • Jeffrey Himawan Ph.D., Independent Chairman of the Board
  • Yuichi Iwaki M.D., Ph.D., President, Chief Executive Officer, Director
  • Ryan Selhorn, Chief Financial Officer
  • Geoffrey G. O'Brien J.D., Vice President
  • Masatsune Okajima, Vice President, Head - Japanese Office
  • Kazuko Matsuda M.D., Ph.D., Chief Medical Officer
  • Yoshio Ishizaka, Independent Director
  • Yutaka Kobayashi, Independent Director

Who owns MediciNova stock?

MediciNova's stock is owned by a variety of of retail and institutional investors. Top institutional investors include KISSEI PHARMACEUTICAL COMPANY ., LTD. (4.10%). Company insiders that own MediciNova stock include Geoffrey Obrien and Yutaka Kobayashi. View Institutional Ownership Trends for MediciNova.

How do I buy MediciNova stock?

Shares of MediciNova can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MediciNova's stock price today?

One share of MediciNova stock can currently be purchased for approximately $5.31.


MarketBeat Community Rating for MediciNova (NASDAQ MNOV)
Community Ranking:  3.7 out of 5 (  )
Outperform Votes:  26 (Vote Outperform)
Underperform Votes:  9 (Vote Underperform)
Total Votes:  35
MarketBeat's community ratings are surveys of what our community members think about MediciNova and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for MediciNova (NASDAQ:MNOV) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: N/A

Analysts' Ratings History for MediciNova (NASDAQ:MNOV)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/18/2017Credit Suisse GroupInitiated CoverageOutperform -> OutperformHighView Rating Details
3/21/2016Ladenburg Thalmann Financial ServicesBoost Price TargetBuy$6.00 -> $11.00N/AView Rating Details
(Data available from 7/26/2015 forward)

Earnings

Earnings History for MediciNova (NASDAQ:MNOV)
Earnings by Quarter for MediciNova (NASDAQ:MNOV)
Earnings History by Quarter for MediciNova (NASDAQ MNOV)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/29/2015Q3 2015($0.10)($0.06)ViewN/AView Earnings Details
7/30/2015Q2 2015($0.10)($0.09)ViewN/AView Earnings Details
8/8/2013Q2 2013($0.11)($0.14)$0.37 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.13)($0.14)$0.31 millionViewN/AView Earnings Details
11/8/2012Q312($0.14)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for MediciNova (NASDAQ:MNOV)
2017 EPS Consensus Estimate: ($0.38)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.10)($0.10)($0.10)
Q2 20171($0.10)($0.10)($0.10)
Q3 20171($0.09)($0.09)($0.09)
Q4 20171($0.09)($0.09)($0.09)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for MediciNova (NASDAQ:MNOV)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for MediciNova (NASDAQ:MNOV)
Insider Ownership Percentage: 15.20%
Institutional Ownership Percentage: 22.26%
Insider Trades by Quarter for MediciNova (NASDAQ:MNOV)
Insider Trades by Quarter for MediciNova (NASDAQ:MNOV)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/15/2017Yutaka KobayashiDirectorBuy1,000$5.60$5,600.00View SEC Filing  
5/12/2017Yutaka KobayashiDirectorBuy24,000$5.62$134,880.00View SEC Filing  
9/15/2016Yutaka KobayashiDirectorBuy11,800$6.44$75,992.00View SEC Filing  
9/9/2016Yutaka KobayashiDirectorBuy10,000$6.67$66,700.00View SEC Filing  
7/5/2016Geoffrey ObrienVPSell3,300$8.00$26,400.00View SEC Filing  
12/10/2014Yutaka KobayashiDirectorBuy12,000$3.54$42,480.00View SEC Filing  
11/26/2014Yutaka KobayashiDirectorBuy10,000$3.07$30,700.00View SEC Filing  
11/20/2014Yutaka KobayashiDirectorBuy13,000$3.19$41,470.00View SEC Filing  
11/19/2014Yoshio IshizakaDirectorBuy5,000$2.86$14,300.00View SEC Filing  
9/11/2014Yutaka KobayashiDirectorBuy10,000$2.95$29,500.00View SEC Filing  
9/3/2014Yutaka KobayashiDirectorBuy15,000$2.66$39,900.00View SEC Filing  
12/12/2013Tatsuo IzumiDirectorSell71,270$2.10$149,667.00View SEC Filing  
11/18/2013Tatsuo IzumiDirectorBuy1,270$2.21$2,806.70View SEC Filing  
5/21/2013Arlene MorrisDirectorSell8,800$3.28$28,864.00View SEC Filing  
5/13/2013Tatsuo IzumiDirectorBuy158,730$3.15$499,999.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for MediciNova (NASDAQ:MNOV)
Latest Headlines for MediciNova (NASDAQ:MNOV)
Source:
DateHeadline
finance.yahoo.com logoMediciNova Announces Positive Results from a Glioblastoma Animal Model Study Presented at the 2017 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois
finance.yahoo.com - June 5 at 7:15 PM
americanbankingnews.com logoMediciNova, Inc. (MNOV) Director Yutaka Kobayashi Purchases 24,000 Shares
www.americanbankingnews.com - May 15 at 7:50 PM
americanbankingnews.com logoFY2017 Earnings Forecast for MediciNova, Inc. (MNOV) Issued By Zacks Investment Research
www.americanbankingnews.com - May 8 at 9:46 AM
americanbankingnews.com logoMediciNova (MNOV) Receives Daily Media Sentiment Rating of -0.20
www.americanbankingnews.com - May 4 at 10:36 AM
americanbankingnews.com logoSomewhat Positive Media Coverage Very Likely to Impact MediciNova (MNOV) Share Price
www.americanbankingnews.com - April 27 at 4:34 PM
streetinsider.com logoPre-Open Stock Movers 04/26: (AKBA) (IRTB) (TWTR) Higher; (X) (STX) (CREE) Lower (more...)
www.streetinsider.com - April 26 at 6:43 PM
nasdaq.com logoMid-Morning Market Update: Markets Edge Higher; Twitter Earnings Beat Views
www.nasdaq.com - April 26 at 6:43 PM
finance.yahoo.com logoMediciNova Announces Exploratory Interim Clinical Outcomes Data from Clinical Trial of MN-166 (ibudilast) …
finance.yahoo.com - April 26 at 6:43 PM
finance.yahoo.com logoMediciNova Announces Exploratory Interim Clinical Outcomes Data from Clinical Trial of MN-166 (ibudilast) in ALS Presented at the American Academy of Neurology (AAN) 69th Annual Meeting  in Boston
finance.yahoo.com - April 26 at 6:43 PM
americanbankingnews.com logoMediciNova (MNOV) Earning Very Positive Press Coverage, AlphaOne Reports
www.americanbankingnews.com - April 23 at 8:08 AM
americanbankingnews.com logoMediciNova (MNOV) Receives Daily Coverage Optimism Rating of 0.02
www.americanbankingnews.com - April 20 at 9:47 PM
americanbankingnews.com logoMediciNova, Inc. (MNOV) Coverage Initiated at Credit Suisse Group AG
www.americanbankingnews.com - April 18 at 4:26 PM
nasdaq.com logoMediciNova Announces MN-166 (ibudilast) Glioblastoma Abstract Selected for Presentation at the 2017
www.nasdaq.com - April 10 at 10:25 AM
finance.yahoo.com logoMediciNova Announces MN-166 (ibudilast) Glioblastoma Abstract Selected for Presentation at the 2017 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois
finance.yahoo.com - April 10 at 10:25 AM
seekingalpha.com logoMediciNova's MN-166: Good Trial, But What About Generic Riluzole?
seekingalpha.com - March 29 at 9:43 AM
finance.yahoo.com logoMNOV: MN-166 Making Progress in Numerous Indications…
finance.yahoo.com - February 27 at 6:04 PM
finance.yahoo.com logoMediciNova Announces MN-166 (ibudilast) Glioblastoma Abstract Selected for Presentation at the 5th Quadrennial Meeting of the World Federation of Neuro-Oncology Societies in Zurich, Switzerland
finance.yahoo.com - February 27 at 6:04 PM
biz.yahoo.com logoMEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure
biz.yahoo.com - February 16 at 6:10 PM
biz.yahoo.com logoMEDICINOVA INC Files SEC form 10-K, Annual Report
biz.yahoo.com - February 14 at 8:09 PM
benzinga.com logoMediciNova Announces MN-166 (ibudilast) ALS...
www.benzinga.com - February 8 at 1:14 AM
finance.yahoo.com logoMediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the American Academy of Neurology (AAN) 69th Annual Meeting in Boston
finance.yahoo.com - February 7 at 7:55 PM
nasdaq.com logoLeading addiction researchers discuss MN-166 in symposium on novel pharmacotherapies to treat substance use disorders
www.nasdaq.com - February 6 at 6:41 PM
finance.yahoo.com logoMediciNova Announces Positive Findings from Completed Trial of MN-166 (ibudilast) in Methamphetamine Dependence Presented at the 50th Winter Conference on Brain Research
finance.yahoo.com - February 6 at 6:41 PM
finance.yahoo.com logoMediciNova to Attend Mizuho Healthcare Conference in New York
finance.yahoo.com - February 1 at 7:31 PM
streetinsider.com logoMedicinova (MNOV) Positive MN-166 Data Published in Neuropsychopharmacology
www.streetinsider.com - January 23 at 6:55 PM
finance.yahoo.com logoMediciNova Announces Publication of Positive Findings on MN-166 (ibudilast) in Alcohol Dependence
finance.yahoo.com - January 23 at 6:55 PM
finance.yahoo.com logoMNOV: Phase 2b Trial of MN-166 in Progressive MS Will Continue to Conclusion
finance.yahoo.com - December 22 at 6:54 PM
streetinsider.com logoMedicinova (MNOV) Announces EU Orphan Medicinal Product Designation for MN-166
www.streetinsider.com - December 21 at 9:40 AM
streetinsider.com logoMedicinova (MNOV) Says Phase 2b Trial of MN-166 in MS Will Continue Following DSMB Review
www.streetinsider.com - December 20 at 12:30 PM
us.rd.yahoo.com logo6:09 am MediciNova announces the phase 2b trial of MN-166 in progressive MS will continue as planned following DSMB review of interim efficacy analysis; expects to receive final data analysis from the study in the 2H17
us.rd.yahoo.com - December 19 at 10:14 AM
finance.yahoo.com logo6:00 am MediciNova announces exploratory interim clinical outcomes data from clinical trial of MN-166 (ibudilast) in ALS presented at the 27th International Symposium on ALS/MND
finance.yahoo.com - December 9 at 9:08 AM
finance.yahoo.com logoMediciNova Announces Exploratory Interim Clinical Outcomes Data from Clinical Trial of MN-166 (ibudilast) in ALS Presented at the 27th International Symposium on ALS/MND in Dublin, Ireland
finance.yahoo.com - December 9 at 9:08 AM
finance.yahoo.com logoMediciNova to Present at the Piper Jaffray Healthcare Conference in New York
finance.yahoo.com - November 14 at 10:20 AM
biz.yahoo.com logoMEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - November 10 at 5:56 PM
finance.yahoo.com logoMediciNova Announces European Medicines Agency Recommends Orphan Medicinal Product Designation for MN-166 …
finance.yahoo.com - November 10 at 8:59 AM
finance.yahoo.com logoMediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 27th International Symposium on ALS/MND in Dublin, Ireland
finance.yahoo.com - October 31 at 12:53 PM
finance.yahoo.com logoMEDICINOVA INC Financials
finance.yahoo.com - October 29 at 5:55 PM
finance.yahoo.com logoMNOV: Interim Analysis of MN-166 in Progressive MS in 4Q16; ODD granted to MN-166 for ALS
finance.yahoo.com - October 27 at 6:17 PM
streetinsider.com logoMedicinova (MNOV) Updates on FY16 Outlook
www.streetinsider.com - October 26 at 6:14 PM
streetinsider.com logoMedicinova's (MNOV) MN-166 Granted FDA Orphan Drug Designation as ALS Treatment
www.streetinsider.com - October 12 at 11:30 AM
finance.yahoo.com logoMediciNova Announces FDA Granted Orphan Drug Designation to MN-166 (ibudilast) for Amyotrophic Lateral Sclerosis
finance.yahoo.com - October 12 at 11:30 AM
biz.yahoo.com logoMEDICINOVA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
biz.yahoo.com - September 16 at 5:59 PM
finance.yahoo.com logoMNOV: Interim Analysis For Phase 2b Trial of MN-166 in Progressive MS in 4Q16
finance.yahoo.com - July 29 at 12:00 PM
nasdaq.com logoMediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis
www.nasdaq.com - July 26 at 6:33 PM
rttnews.com logoNVCR Up On FDA Nod, PeriCoach Now Available OTC, FDA Panel Backs GP2015
www.rttnews.com - July 14 at 6:29 PM
streetinsider.com logoMedicinova (MNOV) Announces Presentation of MN-166 Results in AUD
www.streetinsider.com - June 30 at 9:07 AM

Social

Chart

MediciNova (MNOV) Chart for Wednesday, July, 26, 2017

This page was last updated on 7/26/2017 by MarketBeat.com Staff